Phase 3 Stroke Trial, Recruiting NCT06591390 Sponsor: Kafrelsheikh University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06591390
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years, of any gender
  • People who are experiencing their first-ever minor stroke or TIA (a brief stroke-like episode)
  • People who started antiplatelet medication (a type of blood-thinning tablet) within the first 24 hours of their stroke symptoms beginning
  • People who are not eligible for the clot-dissolving treatment called rt-PA

Who may not be able to join:

  • People who are unable to attend follow-up visits for 90 days after joining the trial
  • People whose stroke symptoms were very mild (NIHSS score below 5) or whose symptoms cleared up quickly before brain imaging was completed
  • People with a known ongoing or recurring brain or nervous system condition, such as epilepsy, a brain tumour called meningioma, multiple sclerosis, or a past head injury that left lasting neurological effects
  • People who had a seizure at the time their stroke began
  • People with signs of major organ failure, active cancer, or a heart attack within the past six weeks
  • People who were taking warfarin, ticagrelor regularly in the week before admission, or chemotherapy within the past year
  • People with an active stomach ulcer, recent gut surgery, or any bleeding episode within the past year
  • People who had major surgery within the past three months
  • People with a known allergy to any of the study medications
  • People with certain abnormal blood test or vital sign results on admission, including blood clotting levels, blood sugar levels, blood pressure, or platelet counts outside of the accepted ranges (confirm with trial site for exact values)
  • People who are pregnant or breastfeeding
  • People whose stroke was caused by a blood clot in a vein (venous thrombosis) rather than an artery
  • People whose stroke occurred after a cardiac arrest or a severe drop in blood pressure
  • People with any medical reason that makes the study drugs unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: mohamed G. Zeinhom, MD, neurology department kafr el-sheikh university

Phone: 2001009606828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
9 February 2022
Est. completion
15 September 2024

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

rate of new stroke; Rate of drug-related hemorrhagic complications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov